Related Experiment Video
Updated: Jan 17, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
The changes in imaging following proton beam therapy for pediatric hepatoblastoma
Dao-Chen Lin1,2,3, Jen-Yin Hou4, Chen-Kan Tseng5
1Department of Radiology, Taipei Veterans General Hospital, Taipei City, Taiwan.
Abstract:
Surgical resection or liver transplantation is the cornerstone of curative treatment for hepatoblastoma (HBL). For unresectable HBL, liver transplantation has proven to be a definitive curative option, with long-term survival rates ranging from 30 to 95% in previous studies. However, some patients may not meet the surgical or medical criteria for transplantation. Traditionally, radiotherapy (RT) has not been a standard treatment for HBL due to the risk of high-dose radiation damage to normal liver tissue. Proton beam therapy (PBT), a type of RT, leverages the Bragg peak phenomenon, concentrating the majority of its energy within the last few millimeters of its range. This results in a significantly reduced radiation dose beyond this point, thereby minimizing potential harm to distal radiosensitive structures. PBT has emerged as an alternative treatment option for hepatocellular carcinoma in non-surgical adult patients, but its effects and post-treatment changes in HBL remain under-documented. In this preliminary investigation, we aimed to examine the post-PBT following imaging changes in both HBL and the surrounding liver parenchyma in pediatric patients. What Is Known: • HBL is the most common primary malignancy of liver in children. • In HBL, liver transplantation is indicated for patients with tumors that cannot be managed by surgical resection. What Is New: • PBT may prove to be a promising treatment option for unresectable HBL, with the potential to preserve normal liver tissue. • Understanding the imaging changes in post-PBT tumors and the associated focal liver reaction at various time points is crucial for accurately assessing treatment response and guiding appropriate alternative treatment options.

